T1	Participants 45 92	children with pervasive developmental disorders
T2	Participants 209 256	children with pervasive developmental disorders
T3	Participants 265 508	Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment with risperidone as part of a previously described controlled discontinuation study
T4	Participants 1475 1522	children with pervasive developmental disorders
